ICD-10-CM · General

M34.1

M34.1 captures the limited form of systemic sclerosis defined by the combination of calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia — collectively known as CR(E)ST or CREST syndrome.

Verified May 8, 2026 · 6 sources ↓

Status
Billable
Chapter
13
Related CPT
0
Region
General
Drawn from CDCICD10DataAAPCCMSCdek

Documentation tips

What should appear in the chart to support M34.1.

Source · Editorial brief grounded in 6 cited references ↓

  • Physician must document the specific CREST features present — at minimum two of the five defining components (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia) along with serological evidence such as positive anti-centromere antibodies.
  • Record whether esophageal dysfunction is absent or subclinical; when it is absent, the variant is CRST syndrome — the ICD-10 Alphabetic Index maps both CRST and CREST to M34.1, but the distinction supports clinical specificity in the record.
  • Document all organ-system manifestations separately: pulmonary, neuromuscular, and renal involvement each require additional codes (e.g., J99 for lung involvement, G73.7 for myopathy) — omitting them leaves reimbursable complexity uncoded.
  • Note the treating specialty's confirmed diagnosis label (CREST syndrome, CR(E)ST syndrome, limited systemic sclerosis/scleroderma) explicitly in the assessment — vague language such as 'possible scleroderma' does not support M34.1 as a principal diagnosis in an outpatient setting.
  • If Raynaud's is treated as a separate clinical problem at the same encounter, verify whether it is integral to the M34.1 diagnosis or an independently managed condition before adding a separate Raynaud's code.

Common coding pitfalls

The recurring mistakes coders make with M34.1 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

  • Assigning M34.9 (unspecified systemic sclerosis) when the documentation clearly supports CREST syndrome — M34.1 is more specific and required when the clinical picture fits.
  • Coding M34.1 for localized scleroderma (morphea): L94.0 is the correct code; M34 category Excludes1 bars circumscribed scleroderma from this range entirely.
  • Omitting manifestation codes for documented organ involvement: CREST syndrome frequently affects the lungs and GI tract, and failing to code those complications understates complexity and may trigger a medical necessity denial.
  • Confusing M34.1 with M34.0 (progressive systemic sclerosis): M34.0 represents diffuse cutaneous systemic sclerosis with more aggressive progression — use M34.1 only when the provider documents the limited/CREST subtype.
  • Submitting M34.1 as the supporting diagnosis for amniotic or placental-derived product injections: CMS LCD A59766 explicitly lists M34.1 among codes that do not support medical necessity for those procedures.

Clinical context

Source · Editorial summary grounded in 6 cited references ↓

M34.1 is the billable code for CR(E)ST syndrome, a limited variant of systemic sclerosis (scleroderma) in which fibrotic and vascular changes are predominantly confined to the skin distal to the elbows and knees, with characteristic multi-system features. The ICD-10-CM 'Applicable To' note specifies the full combination: calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia. When esophageal involvement is not prominent, the condition is sometimes called CRST syndrome — both CRST and CREST index directly to M34.1 in the Alphabetic Index.

Use M34.1 instead of M34.0 (progressive systemic sclerosis) when the treating physician documents limited cutaneous involvement consistent with CREST/CR(E)ST. Use M34.9 (systemic sclerosis, unspecified) only when the documentation does not support a more specific subtype. If organ-specific manifestations are documented beyond the five defining CREST features — for example, pulmonary fibrosis or myopathy — assign ancillary manifestation codes alongside M34.1 (e.g., J99 for lung involvement, G73.7 for myopathy in systemic sclerosis).

M34.1 sits under the M34 category, which carries an Excludes1 note for circumscribed scleroderma (L94.0) and neonatal scleroderma (P83.88). Do not assign M34.1 for localized morphea or neonatal presentations — those are categorically excluded. CMS has explicitly listed M34.1 among diagnoses that do not support medical necessity for amniotic/placental-derived product injections for musculoskeletal indications (LCD A59766), so payer policy review is essential before submitting procedure claims under this diagnosis.

Inclusion & exclusion notes

Per the official ICD-10-CM Tabular List.

Source · CDC ICD-10-CM Official Tabular List · 2026

Includes

  • Combination of calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia

Sibling codes

Other billable codes under M34 (laterality / anatomic variants).

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01What does the 'E' in parentheses in CR(E)ST syndrome mean?
The '(E)' denotes esophageal dysfunction, which is present in full CREST syndrome but may be absent or subclinical — in that case the condition is called CRST syndrome. Both terms index to M34.1 in the ICD-10-CM Alphabetic Index.
02How many CREST features must be documented to use M34.1?
Per clinical coding guidance, at least two of the five defining features should be documented along with supporting serological evidence (typically positive anti-centromere antibodies) to support M34.1. The ICD-10-CM 'Applicable To' note lists all five as a combination, but clinical practice recognizes partial presentations.
03Can M34.1 and M34.0 be coded together on the same claim?
No. M34.0 (progressive systemic sclerosis) and M34.1 (CR(E)ST syndrome) represent distinct subtypes of systemic sclerosis. Code whichever the physician documents as the confirmed diagnosis; do not assign both simultaneously.
04Should Raynaud's phenomenon be coded separately when M34.1 is assigned?
Generally no — Raynaud's phenomenon is an integral component of CREST syndrome and is captured within M34.1. Assign a separate Raynaud's code only if the provider documents it as a distinct, separately managed condition.
05Does M34.1 support medical necessity for amniotic or placental-derived product injections?
No. CMS LCD A59766 explicitly lists M34.1 among ICD-10-CM codes that do not support medical necessity for amniotic and placental-derived product injections for musculoskeletal indications. Claims submitted with M34.1 as the supporting diagnosis for those procedures will likely be denied.
06What is the difference between M34.1 and L94.0?
L94.0 is circumscribed scleroderma (localized morphea), a skin-limited condition. M34.1 is a systemic, multi-organ autoimmune disorder. The M34 category carries an Excludes1 note for L94.0, meaning they cannot be coded together — use L94.0 for morphea, M34.1 for confirmed CREST syndrome.
07When should M34.8x manifestation codes be added alongside M34.1?
Add specific systemic sclerosis manifestation codes (e.g., M34.81 for lung involvement, M34.82 for myopathy, M34.83 for polyneuropathy) when those organ complications are documented. Alternatively, use J99 or G73.7 per tabular instructions for respiratory and neuromuscular involvement respectively.

Mira Scribe

Mira AI Scribe captures the specific CREST features documented at the encounter — which of the five components (calcinosis, Raynaud's, esophageal dysfunction, sclerodactyly, telangiectasia) are active, any positive serologic findings (anti-centromere antibodies), and organ-system involvement beyond the defining features. This prevents downcoding to unspecified systemic sclerosis (M34.9) and ensures manifestation codes for pulmonary or neuromuscular complications aren't missed.

See how Mira captures M34.1 documentation

Related ICD-10 codes

Ready to transform your orthopedic practice?

See how orthopedic practices are running documentation, billing, and operations on a single voice-first platform.

Request Access